Search

Your search keyword '"MESH : Thirst"' showing total 2 results
Start Over Descriptor "MESH : Thirst"
2 results on '"MESH : Thirst"'

1. Caring for patients with rabies in developing countries - the neglected importance of palliative care

Author

Hervé Bourhy, Yiksing Peng, Yoann Crabol, Sotheary In, Sowath Ly, Arnaud Tarantola, Philippe Buchy, Hubert Barennes, Bangalore Jayakrishnappa Mahendra, Institut Pasteur du Cambodge, Institut Pasteur du Cambodge-Réseau International des Instituts Pasteur ( RIIP ), Kodagu Institute of Medical Sciences, Dynamique des Lyssavirus et Adaptation à l'Hôte, Institut Pasteur [Paris], GlaxoSmithKline (GSK) Vaccine, Unité d'Épidémiologie et de Santé Publique [Phnom Penh], Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP), Centre Collaborateur de l'OMS pour la Rage - Dynamique des lyssavirus et adaptation à l'hôte (CC-OMS), Unité de Virologie / Virology Unit [Phnom Penh], GlaxoSmithKline, Glaxo Smith Kline, and Institut Pasteur [Paris] (IP)

Subjects
hidrofobia, Palliative care, [SDV]Life Sciences [q-bio], rabies, Epileptic fits, rage, 0302 clinical medicine, tratamiento, MESH : Anxiety, MESH: Rural Population, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Health care, 030212 general & internal medicine, MESH : Palliative Care, MESH : Thirst, MESH: Developing Countries, MESH : Seizures, palliative care, treatment, cvg.computer_videogame, diazépam, MESH: Seizures, 3. Good health, [ SDV.MHEP.MI ] Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Infectious Diseases, cuidados paliativos, soins palliatifs, midazolam, Anxiety, MESH: Palliative Care, medicine.symptom, medicine.medical_specialty, 030231 tropical medicine, Developing country, Hydrophobia, [ SDV.MP.VIR ] Life Sciences [q-bio]/Microbiology and Parasitology/Virology, traitement, 03 medical and health sciences, MESH: Rabies, Intensive care, medicine, hydrophobie, MESH : Developing Countries, cvg, Intensive care medicine, hydrophobia, MESH: Humans, MESH: Anxiety, [ SDV ] Life Sciences [q-bio], business.industry, MESH : Humans, Public Health, Environmental and Occupational Health, developing countries, pays en voie de développement, MESH : Respiratory Insufficiency, medicine.disease, Surgery, MESH: Drugs, Essential, MESH : Rural Population, MESH : Drugs, Essential, países en vías de desarrollo, MESH : Rabies, MESH: Thirst, Parasitology, Rabies, business, Rabia, MESH: Respiratory Insufficiency
Abstract

International audience; Although limited publications address clinical management of symptomatic patients with rabies in intensive care units, the overwhelming majority of human rabies cases occur in the rural setting of developing countries where healthcare workers are few, lack training and drugs. Based on our experience, we suggest how clinicians in resource-limited settings can make best use of essential drugs to provide assistance to patients with rabies and their families, at no risk to themselves. Comprehensive and compassionate patient management of furious rabies should aim to alleviate thirst, anxiety and epileptic fits using infusions, diazepam or midazolam and antipyretic drugs via intravenous or intrarectal routes. Although the patient is dying, respiratory failure must be avoided especially if the family, after being informed, wish to take the patient home alive for funereal rites to be observed. Healthcare staff should be trained and clinical guidelines should be updated to include palliative care for rabies in endemic countries.

Published
2016
Full Text
View/download PDF

2. Roles of brain angiotensins II and III in thirst and sodium appetite

Author

Wendy L. Wilson, Catherine Llorens-Cortes, John W. Wright, Robert C. Speth, Joseph W. Harding, Bernard P. Roques, Department of Psychology, University of Washington [Seattle], Pharmacochimie moléculaire et structurale, Institut des sciences du Médicament -Toxicologie - Chimie - Environnement (IFR71), Institut National de la Santé et de la Recherche Médicale (INSERM)-Ecole Nationale Supérieure de Chimie de Paris - Chimie ParisTech-PSL (ENSCP), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Ecole Nationale Supérieure de Chimie de Paris - Chimie ParisTech-PSL (ENSCP), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD)-Université Paris Descartes - Paris 5 (UPD5)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Neuropeptides centraux et régulations hydrique et cardiovasculaire, Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre interdisciplinaire de recherche en biologie (CIRB), Labex MemoLife, École normale supérieure - Paris (ENS Paris), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Collège de France (CdF (institution))-Ecole Superieure de Physique et de Chimie Industrielles de la Ville de Paris (ESPCI Paris), Université Paris sciences et lettres (PSL)-École normale supérieure - Paris (ENS Paris), Université Paris sciences et lettres (PSL)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Labex MemoLife, Université Paris sciences et lettres (PSL)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM), Department of Pharmacology, and Research Institute in Pharmaceutical Sciences, The University of Mississippi [Oxford], Department of Veterinary and Comparative Anatomy, Pharmacology, and Physiology, Washington State University (WSU), Institut de Recherche pour le Développement (IRD)-Ecole Nationale Supérieure de Chimie de Paris - Chimie ParisTech-PSL (ENSCP), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD)-Ecole Nationale Supérieure de Chimie de Paris - Chimie ParisTech-PSL (ENSCP), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Université Pierre et Marie Curie - Paris 6 (UPMC)-Centre interdisciplinaire de recherche en biologie (CIRB), École normale supérieure - Paris (ENS-PSL), Université Paris sciences et lettres (PSL)-École normale supérieure - Paris (ENS-PSL), Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Labex MemoLife, Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM), Llorens Cortes, Catherine, Institut des sciences du Médicament -Toxicologie - Chimie - Environnement ( IFR71 ), Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Ecole Nationale Supérieure de Chimie de Paris- Chimie ParisTech-PSL ( ENSCP ) -Centre National de la Recherche Scientifique ( CNRS ) -Institut de Recherche pour le Développement ( IRD ) -Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Ecole Nationale Supérieure de Chimie de Paris- Chimie ParisTech-PSL ( ENSCP ) -Centre National de la Recherche Scientifique ( CNRS ) -Institut de Recherche pour le Développement ( IRD ) -Université Paris Descartes - Paris 5 ( UPD5 ) -Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Collège de France ( CdF ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Washington State University ( WSU ), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Ecole Superieure de Physique et de Chimie Industrielles de la Ville de Paris (ESPCI Paris), Université Paris sciences et lettres (PSL)-Collège de France (CdF (institution))-École normale supérieure - Paris (ENS Paris), Université Paris sciences et lettres (PSL)-Collège de France (CdF (institution))-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Labex MemoLife, and Université Paris sciences et lettres (PSL)-Collège de France (CdF (institution))-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)

Subjects
Male, Captopril, Angiotensin III, Appetite, MESH : Dose-Response Relationship, Drug, Angiotensin-Converting Enzyme Inhibitors, MESH: Rats, Sprague-Dawley, 030204 cardiovascular system & hematology, Thirst, MESH: Dose-Response Relationship, Drug, Rats, Sprague-Dawley, MESH: Furosemide, 0302 clinical medicine, Methionine, Sodium Potassium Chloride Symporter Inhibitors, Furosemide, MESH: Animals, MESH : Thirst, media_common, computer.programming_language, [SDV.MHEP.EM] Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism, Chemistry, sed, MESH : Rats, General Neuroscience, Angiotensin II, MESH : Sodium Chloride, Dietary, MESH: Angiotensin-Converting Enzyme Inhibitors, Brain, MESH : Injections, Intraventricular, [ SDV.MHEP.EM ] Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism, MESH: Angiotensin III, [SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism, MESH : Furosemide, MESH : Angiotensin-Converting Enzyme Inhibitors, MESH: Angiotensin II, medicine.symptom, MESH: Injections, Intraventricular, hormones, hormone substitutes, and hormone antagonists, medicine.drug, MESH : Appetite, medicine.medical_specialty, MESH: Rats, media_common.quotation_subject, Sodium, MESH : Male, MESH : Sulfonic Acids, MESH : Captopril, chemistry.chemical_element, MESH : Angiotensin II, 03 medical and health sciences, MESH: Brain, Internal medicine, MESH : Angiotensin III, Renin–angiotensin system, medicine, Animals, Sodium Chloride, Dietary, MESH: Sodium Chloride, Dietary, Molecular Biology, Injections, Intraventricular, MESH : Methionine, Dose-Response Relationship, Drug, MESH: Captopril, MESH : Rats, Sprague-Dawley, MESH: Male, Rats, Endocrinology, MESH : Brain, MESH: Methionine, MESH : Sodium Potassium Chloride Symporter Inhibitors, MESH: Sulfonic Acids, MESH: Thirst, MESH: Appetite, Neurology (clinical), MESH : Animals, MESH: Sodium Potassium Chloride Symporter Inhibitors, Sulfonic Acids, computer, 030217 neurology & neurosurgery, Developmental Biology
Abstract

International audience; The current study examined the effects of intracerebroventricular (icv) infused aminopeptidase-resistant analogs of angiotensin II (AngII) and angiotensin III (AngIII) on thirst and sodium appetite. The analogs, [D-Asp1D-Arg2]AngII and [D-Arg1]AngIII, were further protected from degradation by pretreatment with the aminopeptidase A inhibitor, EC33, or the aminopeptidase N inhibitor, PC18. Prior to icv infusions, rats were sodium depleted with furosemide, followed by the angiotensin-converting enzyme inhibitor captopril, to block endogenous angiotensin formation. Both angiotensin analogs, at either of the two doses, were capable of eliciting fluid intakes of water and 0.3 M NaCl. Water and saline intakes were increased to a similar extent by 125 and 1250 pmol of [D-Asp1D-Arg2]AngII. [D-Arg1]AngIII produced a dose-dependent increase in water intake, whereas saline intake was equivalently increased by the 125 and 1250 pmol infusions. Pretreatment with EC33 or PC18 decreased water and saline intakes in response to [D-Asp1D-Arg2]AngII, while pretreatment with PC18 altered the time course of the [D-Arg1]AngIII-induced water and saline intakes. The ability of both inhibitors to decrease, but not completely block, AngII analog-induced intakes, coupled with the altered time course of the responses induced by the AngIII analog in the presence of PC18, supports the hypothesis that both AngII and AngIII are active ligands in brain angiotensin-mediated thirst and sodium appetite. However, these results do not resolve the primary question of whether conversion of AngII to AngIII is a prerequisite to dipsogenic and salt appetite responses in the brain.

Published
2005
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results